跳轉至內容
Merck
全部照片(1)

重要文件

1603800

USP

Rifabutin

United States Pharmacopeia (USP) Reference Standard

同義詞:

Ansamycin, Ansatipine (Farmitalia), LM-427, Mycobutin (Farmitalia)

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C46H62N4O11
CAS號碼:
分子量::
847.00
MDL號碼:
分類程式碼代碼:
41116107
NACRES:
NA.24
暫時無法取得訂價和供貨情況

等級

pharmaceutical primary standard

API 家族

rifabutin

製造商/商標名

USP

應用

pharmaceutical (small molecule)

形式

neat

SMILES 字串

[N+H]1(CCC2(NC3=C4NC(=O)\C(=C/C=C/[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]([C@H](\C=C\O[C@]5(Oc6c(c(c(c(c6C)[O-])C4=O)C3=N2)C5=O)C)OC)C)OC(=O)C)C)O)C)O)C)\C)CC1)CC(C)C

InChI

1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,49,52-54H,16-19,21H2,1-11H3,(H,47,57)/b13-12+,20-15+,24-14-/t23-,25+,26+,27+,30-,37-,38+,41+,45-/m0/s1

InChI 密鑰

ATEBXHFBFRCZMA-VXTBVIBXSA-N

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Rifabutin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Rifabutin Capsules
  • Rifabutin Compounded Oral Suspension

生化/生理作用

Rifabutin is an antibiotic; antitumor.
Rifabutin is an antibiotic; antitumor. Rifabutin interferes with HSP-90 molecular chaperone, enhances ubiquitination and protein degradation, and inactivates bacterial RNA polymerase.

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

Anne M Baciewicz et al.
The American journal of the medical sciences, 335(2), 126-136 (2008-02-16)
Rifampin is a potent inducer of cytochrome P-450 oxidative enzymes as well as the P-glycoprotein transport system. Several examples of well-documented clinically significant interactions include warfarin, oral contraceptives, cyclosporine, itraconazole, digoxin, verapamil, nifedipine, simvastatin, midazolam, and human immunodeficiency virus-related protease
Is rifabutin prophylaxis against Mycobacterium avium complex infection in HIV infection worthwhile? The net impact on patients suggests not.
J M Stephenson et al.
Genitourinary medicine, 72(4), 272-276 (1996-08-01)
G Davies et al.
The Cochrane database of systematic reviews, (4)(4), CD005159-CD005159 (2007-10-19)
Rifamycins are an essential component of modern short-course regimens for treating tuberculosis. Rifabutin has favourable pharmacokinetic and pharmacodynamic properties and is less prone to drug-drug interactions than rifampicin. It could contribute to shortening of therapy or simplify treatment in HIV-positive
R E Chaisson
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 22 Suppl 1, S61-S66 (1996-04-01)
Patients with advanced human immunodeficiency virus (HIV) disease are at risk for infections caused by protozoa, fungi, viruses, bacteria, and mycobacteria. Chemoprophylaxis is being used increasingly to prevent a growing number of opportunistic infections that occur in HIV-infected patients. Multiple
Marta Sousa et al.
The Journal of antimicrobial chemotherapy, 62(5), 872-878 (2008-08-21)
Malaria and tuberculosis (TB) are two major global diseases mostly affecting the developing countries. Their treatment is often complex because of the drugs used, multidrug resistance, drug interactions and logistic problems such as drug availability and access. Patients are treated

Questions

Reviews

No rating value

Active Filters

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務